Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01064466 · ClinicalTrials.gov registry record · Phase 2

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

A Phase 2 study of Small-cell Lung Cancer, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.

Active
Registry status
Phase 2
Development phase
600
Enrollment target
1
Study location

NCT01064466 is a Phase 2 study of Small-cell Lung Cancer that is active but no longer recruiting, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. The registered enrollment target is 600 participants, above the 225-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (167% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01064466, a Phase 2 study of Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

Explore the relationship between drug target topoisomerase II gene single nucleotide polymorphisms and Etoposide (VP-16) therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and Etoposide (VP-16) side-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.

Conditions Studied

Small-cell Lung Cancer

Interventions

  • DRUG ETOPOSIDE - Usual
  • DRUG ETOPOSIDE - Study

Study Locations (1)

Maryland

  • Medicine Invention Design, Inc. (MIDI) - IORG0007849 - NPI 1023387701 - Rockville

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2025-07-16
Est. Completion 2026-12-28
Phase Phase 2

Sponsor

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01064466

The ClinicalTrials.gov registry entry for NCT01064466 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 225-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (167% higher). The listed sponsor is Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which ETOPOSIDE - Usual is the first listed.

NCT01064466 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT01064466 about?

NCT01064466 is a clinical study titled "Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms". Explore the relationship between drug target topoisomerase II gene single nucleotide polymorphisms and Etoposide (VP-16) therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene...

What is the current status of trial NCT01064466?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2025-07-16. Estimated completion is 2026-12-28.

What conditions does trial NCT01064466 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer.

What interventions are being tested in trial NCT01064466?

The interventions under investigation include: ETOPOSIDE - Usual (DRUG), ETOPOSIDE - Study (DRUG).

Who is sponsoring clinical trial NCT01064466?

This trial is sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01064466 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small-cell Lung Cancer

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.